Tempus AI, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Eric Lefkofsky
- Full Time Employees
- 2,400
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- 600 West Chicago Avenue Chicago IL United States of America 60654
- IPO Date
- Jun 14, 2024
- CIK
- 0001717115
- Website
- tempus.com
- Similar Companies
- Business
- Tempus AI, Inc. operates as an innovative healthcare technology firm, dedicated to transforming patient care through the application of artificial intelligence. The company specializes in delivering comprehensive genomic sequencing diagnostics, including next-generation sequencing, polymerase chain reaction profiling, and advanced molecular pathology testing to a broad spectrum of healthcare entities. These clients include medical providers, pharmaceutical manufacturers, biotechnology innovators, and research institutions. The organization provides a suite of advanced platforms such as Tempus Lens, designed for scientists to explore, access, and analyze de-identified clinical, molecular, and imaging data, and Tempus Hub, a streamlined desktop and mobile interface for managing test orders and patient results. Their offerings also encompass predictive algorithmic tests, like Algos and Next, tailored for oncology and other therapeutic areas, as well as Trials, a service that facilitates patient matching for clinical studies. Tempus AI generates revenue primarily through its genomic testing services, data licensing, and clinical trial solutions. The company notably expanded its reach by going public on Nasdaq in June 2024 under the ticker TEM. Recent strategic developments include the November 2024 acquisition of Ambry Genetics, a $600 million deal, and the formation of SB Tempus, an AI healthcare joint venture in Japan with SoftBank. In April 2025, Tempus AI, AstraZeneca, and Pathos AI announced multi-year agreements, including $200 million in data licensing and model development fees to Tempus, to co-develop a significant multimodal foundation model in oncology, building on an earlier 2021 partnership. Further collaborations in 2025 include a partnership with Illumina for genomic testing integration and research alliances with Northwestern University for Alzheimer's disease and the Institute for Follicular Lymphoma Innovation. Headquartered in Chicago, Illinois, Tempus AI was established in 2015 and remains at the forefront of leveraging large-scale multimodal data and AI to accelerate precision medicine, with a significant presence among U.S. oncologists and top biopharma companies.
Should You Retain Tempus AI Stock In Your Portfolio Now?
Tempus AI (TEM) Price Forecast: Consolidation Bottom Breakout Looms
Tempus AI: AI Precision Medicine With A Moat
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm
Tempus AI: The Compression Has Outrun The Business - Upgrading To Buy
Tempus AI: A Unique AI Business Model With Asymmetric Upside
Genetics in Medicine Open Study Demonstrates How Ambry Genetics' ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing
Tempus AI, Inc. (TEM) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Great News: This Explosive Healthcare Stock Could Be a Powerful Artificial Intelligence Winner
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
Why Is Tempus (TEM) Down 11.2% Since Last Earnings Report?
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members
AI News You Need to Know — June Edition: Capex, Inference, & Beyond
Tempus AI, Inc. (TEM) Analyst/Investor Day Transcript
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH
Consumer Tech News (May 25-29): Dell, IBM, CrowdStrike, Meta Lead Big Tech AI Push
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
Tempus Introduces 'Preview': Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results